Skip to content

Other financials

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation

See full
Market cap$1.71B-23.7%
Enterprise value$1.14B-39.8%
P/S25.8×-11.8×

Profitability

See full
Gross margin7.2%
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Recursion Pharmaceuticals, Inc.'s trademarks.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s trademarks?
Recursion Pharmaceuticals, Inc. (RXRX) reported trademarks of $135.55M in Q1 2026.
How has Recursion Pharmaceuticals, Inc.'s trademarks changed year-over-year?
Recursion Pharmaceuticals, Inc.'s trademarks increased by 2.1% year-over-year, from $132.74M to $135.55M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s trademarks?
Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s trademarks has grown at a 173.4% compound annual growth rate (CAGR), from $904K to $138.02M.